Duodenal ReCET Plus Semaglutide Can Prevent Need for Insulin in T2DM

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 24, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Oct. 24, 2024 -- For patients with type 2 diabetes (T2D), duodenal recellularization via electroporation therapy (ReCET), which uses pulsed electric fields to induce natural cell death through an apoptosis-like process, is feasible and safe and can prevent the need for insulin therapy when combined with semaglutide, according to a study presented at UEG Week, the annual meeting of United European Gastroenterology, held from Oct. 4 to 7 in Vienna.

Celine Busch, M.D., from Amsterdam University Medical Center, and colleagues presented 24-month results from a single-arm, single-center, first-in-human study conducted in 14 patients with T2D. All patients underwent the ReCET procedure, followed by a two-week isocaloric liquid diet; semaglutide was titrated up to 1 mg/week thereafter.

The researchers found that the technical success rate of the ReCET procedure was 100 percent; the median axial treatment length was 12 cm, and median procedure time was 58 minutes. There were no serious adverse events related to the device or severe hypoglycemic events. Thirteen of the patients (93 percent) tolerated the maximum dose of semaglutide. Twelve patients (86 percent) were still not using insulin at six and 12 months, but they had significant improvements in glycemic control and metabolic parameters. All 11 patients who completed the 24-month follow-up remained off insulin with adequate glycemic control.

"These findings are very encouraging, suggesting that ReCET is a safe and feasible procedure that, when combined with semaglutide, can effectively eliminate the need for insulin therapy," Busch said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-25 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords